Simplify Logo

Internship

Patient Supply Co-op

Confirmed live in the last 24 hours

Beam Therapeutics

Beam Therapeutics

201-500 employees

Develops precision genetic medicines using base editing

Biotechnology
Healthcare

Cambridge, MA, USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • Pursuing a Bachelor's degree in Biology, Nursing, Supply Chain, or related field.
  • Self-starter with good organization skills, project management, and attention to detail.
  • Strong interpersonal communication and collaboration skills; must effectively operate independently, across functional lines, and with internal customers.
  • Proficient computer skills (MS PowerPoint, Excel, Word and windows-based software), SmartSheet experience a plus.
  • Some travel may be required.
Responsibilities
  • Support in Patient Scheduling, Clinical Supplies Planning and Forecasting as required to meet program objectives, works with Clinical Operations and CMC to ensure timing of clinical trial investigational material needs are met.
  • Assist in creating packaging strategies and label text for multiple countries/regions. This may include assisting with packaging, labeling, national and international shipping/distribution operations for IMP (Investigational Medicinal Product) to ensure on time delivery to support clinical trials.
  • Assist in the development of clinical study protocols and pharmacy manuals. This may include visibility to how clinical dose preparation and administration strategies are created for complex gene editing products in early phases of development.
  • Coordinate input and support to develop training materials.
  • Participate in the development and implementation of Patient Supply digital tools that inform business decisions and enable business execution.
  • Other duties as assigned.

Beam Therapeutics develops precision genetic medicines using a technique called base editing, which allows for precise modifications to the genetic code to potentially correct mutations that lead to serious diseases. Their primary focus is on treating genetic disorders, such as sickle cell disease, with the aim of providing lifelong cures instead of temporary solutions. The company invests significantly in research and development to create new therapies and generates revenue through partnerships, licensing agreements, and future commercialization of their treatments. Unlike many competitors, Beam Therapeutics emphasizes collaboration with pharmaceutical companies and research institutions, which helps them secure funding and advance their projects. Their goal is to advance scientific research and deliver effective, long-lasting treatments for patients.

Company Stage

IPO

Total Funding

$689M

Headquarters

Cambridge, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

4%

1 year growth

-8%

2 year growth

-7%
Simplify Jobs

Simplify's Take

What believers are saying

  • Beam Therapeutics' innovative base editing technology has the potential to revolutionize the treatment of genetic disorders, offering hope for lifelong cures.
  • The company's strong pipeline, including early-stage studies for sickle cell disease, positions it well for future growth and breakthroughs.
  • Significant investments and partnerships, like the recent $250 million deal with Eli Lilly, enhance Beam's financial stability and research capabilities.

What critics are saying

  • The recent retirement of CFO Terry-Ann Burrell and the layoff of 20% of staff could lead to operational disruptions and affect company morale.
  • Beam's focus on early-stage studies means that its treatments are still years away from commercialization, posing a risk to short-term revenue generation.

What makes Beam Therapeutics unique

  • Beam Therapeutics leverages base editing technology, which allows for precise genetic modifications, setting it apart from traditional gene-editing methods like CRISPR.
  • The company's focus on developing lifelong cures for genetic disorders, rather than temporary treatments, distinguishes it in the biotechnology sector.
  • Beam's strategic partnerships and licensing agreements, such as the $250 million deal with Eli Lilly, provide significant financial backing and collaborative opportunities.

Help us improve and share your feedback! Did you find this helpful?